EVALUATION OF MARKERS OF TARGET ORGANS PRECLINICAL DAMAGE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE COMBINED WITH METABOLIC SYNDROME DEPENDING ON THE OBESITY STAGE

O. I. Kocherzhat

O. I. Kocherzhat Ivano-Frankivsk National Medical University, 2 Halytska st., Ivano-Frankivsk, 76000 Ukraine

Keywords: non-alcoholic fatty liver disease, metabolic syndrome, obesity.

Abstract

Purpose. Тo assess the indicators of early predictors of NAFLD in patients with MS by assessing the functional state of the liver and systemic inflammation, depending on the degree of obesity.

Material and methods. The study included 90 patients with NAFLD, divided in to 3 groups: group 1 – 30 patients with NADH without MS, group 2 – patients with NADH combined with MS: with BMI 25 – 29.9 kg/m² (n = 30) – group 2a, with BMI > 30 kg/m² (n = 30) – group 2b. The control group consisted of 20 apparently healthy individuals. All patients were evaluated for the activity of ALT, AST, LDH, SDH, CHE, total bilirubin level; levels of leptin, adiponectin, TNF-α.

Results. Significant increase in the level of SDH in patients of both groups was found. In patients of group 2a LDH level exceeded the value in healthy persons by 2.5 times (p < 0.05) and was 1.3 times higher than in patients of group 1 (p < 0.05); in patients of group 2b was exceeded the control index in 3.7 times (p < 0.05), in 1,6 times as compared to the patients of group 1 (p < 0.05) and 1,3 times in comparison with patients of group 2a (p < 0.05). The activity of CHE in patients of group 1 significantly was not different from the index of control (p > 0.05), in patients of group 2b significant decrease of CHE activity was found (р < 0.05). The presence of hyperleptinemia, hypoadiponectinemia, and systemic inflammatory response according to the level of TNF -α was characteristic for patients with NAFLD and MS.

Conclusions. Hyperleptinemia, hypoadiponectinemia, the presence of a systemic inflammatory response to the level of TNF-α, and a violation of the synthetic and detoxification functions of the liver, which are more pronounced in patients with NAFLD and MS with concomitant obesity of І–ІІІ degrees, can be considered not only as markers of preclinical lesions of target organs, but and as an indicators of the severity of the combined flow of NAFLD and MS.

Downloads

Download data is not yet available.

References

1. Tkach SM. [Non-alcoholic fatty liver disease: incidence, natural history, new approaches to diagnostic and treatment]. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2016;1(1):60-71.
2. Kharchenko NV, Lishchyshyna OM, Anokhina HA. Adaptovana klinichna nastanova, zasnovana na dokazakh «Nealkoholna zhyrova khvoroba pechinky» [Adapted clinical guidance, based on the evidence "Non-alcoholic fatty liver disease"]. Retrieved from: http://www.moz.gov.ua/docfiles/dod_akn_dn_20140616_2.pdf
3. Chen LZ, Xin Xin YN, Geng N. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver. World J Gastroenterol. 2015;21(3):794–802.
4. Kriuchko TO. [Metabolic syndrome as a basic for nonalcoholic fatty liver disease development in obese children]. Zdorove rebenka. 2014;4(4):21-25.
5. Khobzei MK, Kharchenko NV, Lishchyshyna OM. [Unified clinical protocol "Non-alcoholic steatohepatitis"; Order of the Ministry of Health of Ukraine No. 826 dated 06.11.2014]. Retrieved from: http://moz.gov.ua/docfiles/dn_20141106_0826_dod_ukp_nsg.pdf
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
7. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology 2016;64(6):1388-1402
8. Ambrosova TM. [Adipocines in metabolic syndrome: theory of pathogenesis]. Aktualni problemy suchasnoi medytsyny. 2013;13(4):215-220.
9. Iahmur VB. [Non-alcoholic fatty liver disease: modern view on pathogenesis, diagnostic and treatment]. Hastroenterolohiia. 2013;3(3):138-147.
10. Hurjui DM. [Nonalcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome]. Rev. Med. Chir. Soc. Med. Nat. Lasi. 2012;116(3):692699.
11. Younossi ZM, Otgonsuren M, Henry L. [Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009]. Hepatology. 2015; 62(6):1723-1730.
12. Zviahyntseva TD, Hlushchenko SV. [Nonalcoholic Fatty Liver Disease : Early Detection Markers of Fibrosis] Visnyk problem biolohii i medytsyny. 2013;1(4):132-136.
13. Zoller H. [Nonalcoholic fatty liver disease and hepatocellular carcinoma]. Metabol Clin Experim. – 2016;65(8):1151-1160.
14. Trybrat TA, Shut SV, Sakevich VD. [Metabolic Syndrome in the Practice of Family Doctor]. Visnyk problem biolohii i medytsyny. 2015;2(4):36-38.
15. Kovalova OM. [Activity of adipocytokines depending on the presence of insulin resistance in patients with arterial hypertension with obesity]. Medytsyna sohodni i zavtra. 2009;1(1):62-67.
16. Dulai PS, Sirlin CB, Loomba M. [MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH]. Clinical trials to clinical practice. J Hepatol. 2016;65(5):1006-1016.
17. Smolka V, Ehrmann JJ, Tkachyk O. [Relation of risk factors between metabolic syndrome and nonalcoholic fatty liver disease in children and adolescents]. Cas. Lek. Cesk. 2014;153(2):91-97.